2008
Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression
Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF, Chow WH. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes & Control 2008, 20: 361-368. PMID: 18989634, PMCID: PMC2726999, DOI: 10.1007/s10552-008-9250-6.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAnti-Inflammatory Agents, Non-SteroidalBody Mass IndexCarcinoma, Squamous CellCardiaCase-Control StudiesConfidence IntervalsEsophageal NeoplasmsGastroesophageal RefluxHumansImmunohistochemistryLogistic ModelsMiddle AgedMulticenter Studies as TopicOdds RatioPopulation SurveillanceRisk FactorsSmokingStomach NeoplasmsTumor Suppressor Protein p53United StatesConceptsBody mass indexNon-steroidal anti-inflammatory drugsGastroesophageal reflux diseaseRisk factorsP53 overexpressionGastric cancerCigarette smokingReflux diseaseMass indexNon-steroidal anti-inflammatory drug useTumor subtypesPopulation-based case-control studyAnti-inflammatory drug useNon-cardia gastric adenocarcinomaGastro-esophageal reflux diseaseLarger body mass indexNon-cardia gastric cancerEsophageal squamous cell carcinomaTumor p53 overexpressionRisk factor profileSquamous cell carcinomaRisk of subtypesCase-control studyAnti-inflammatory drugsP53 protein overexpression
2005
Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers
Trivers KF, de Roos AJ, Gammon MD, Vaughan TL, Risch HA, Olshan AF, Schoenberg JB, Mayne ST, Dubrow R, Stanford JL, Abrahamson P, Rotterdam H, West AB, Fraumeni JF, Chow WH. Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clinical Gastroenterology And Hepatology 2005, 3: 225-230. PMID: 15765441, DOI: 10.1016/s1542-3565(04)00613-5.Peer-Reviewed Original ResearchConceptsBody mass indexEsophageal squamous cell carcinomaGastric cancerHazard ratioLonger survivalNonsteroidal anti-inflammatory drug usePopulation-based case-control studyAnti-inflammatory drug usePrediagnosis body mass indexAdjusted hazard ratioGastroesophageal reflux diseaseSquamous cell carcinomaConfidence intervalsGastric cancer survivalCase-control studyEsophageal adenocarcinoma patientsLocalized diseaseReflux diseaseMass indexAlcohol intakeCigarette smokingDecreased riskIncident casesAdenocarcinoma patientsCell carcinoma
2004
Nonsteroidal Anti-inflammatory Drug Use Associated with Reduced Incidence of Adenocarcinomas of the Esophagus and Gastric Cardia that Overexpress Cyclin D1A Population-Based Study
Gammon MD, Terry MB, Arber N, Chow WH, Risch HA, Vaughan TL, Schoenberg JB, Mayne ST, Stanford JL, Dubrow R, Rotterdam H, West AB, Fraumeni JF, Weinstein IB, Hibshoosh H. Nonsteroidal Anti-inflammatory Drug Use Associated with Reduced Incidence of Adenocarcinomas of the Esophagus and Gastric Cardia that Overexpress Cyclin D1A Population-Based Study. Cancer Epidemiology Biomarkers & Prevention 2004, 13: 34-39. PMID: 14744730, DOI: 10.1158/1055-9965.epi-03-0198.Peer-Reviewed Original ResearchConceptsCyclin D1 statusOdds ratioCyclin D1NSAID useGastric cardiaRisk factorsCase groupD1 tumorsNonsteroidal anti-inflammatory drug usePopulation-based case-control studyAnti-inflammatory drug useMultivariate-adjusted odds ratioEsophageal squamous cell carcinomaNoncardia gastric adenocarcinomaUse of aspirinSquamous cell carcinomaGastric cancer patientsCase-control studyGastric cardia adenocarcinomaCigarette smokingCell carcinomaCancer patientsGastric adenocarcinomaEsophageal adenocarcinomaReduced incidence